
- /
- Supported exchanges
- / US
- / RPTX.NASDAQ
Repare Therapeutics Inc (RPTX NASDAQ) stock market data APIs
Repare Therapeutics Inc Financial Data Overview
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Repare Therapeutics Inc data using free add-ons & libraries
Get Repare Therapeutics Inc Fundamental Data
Repare Therapeutics Inc Fundamental data includes:
- Net Revenue: 1 073 K
- EBITDA: -128 276 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.63
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Repare Therapeutics Inc News

Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023
Revenue: Reported a decrease to $13.0 million in Q4 and $51.1 million for the full year, compared to the previous year. Net Loss: Increased net loss to $28.0 million in Q4 and $93.8 million for the fu...


Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial Repare is eligible to receive up to $1.2 billion in potential...

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
CAMBRIDGE, Mass. & MONTREAL, January 08, 2024--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided...

Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
Collaborative clinical study will investigate a novel combination of lunresertib, Repare’s first-in-class PKMYT1 inhibitor, and Debio 0123, Debiopharm’s potent, brain-penetrant inhibitor of WEE1 ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.